Junqiang Ding
Impact in
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
- Microbiology top 10%
- Antimicrobial Peptides and Activities
Papers in
-
- Immunotherapy and Immune Responses 5
- Immune cells in cancer 5
- Phagocytosis and Immune Regulation 2
- Co-authors
- Yanzhi Song (12 shared papers)Xinrong Liu (9 shared papers)Xihui Gao (6 shared papers)Yihui Deng (9 shared papers)Xiaoxiao Liu (5 shared papers)Wuyuan Lu (2 shared papers)Chongbing Liao (1 shared paper)Mingqi Liu (5 shared papers)
- Journals
- Molecular Pharmaceutics (2 papers)International Journal of Pharmaceutics (2 papers)Acta Pharmaceutica Sinica B (1 paper)ACS Biomaterials Science & Engineering (1 paper)Pharmaceutics (1 paper)
- Partner nations
- ChinaSouth Korea
In The Last Decade
Junqiang Ding
18 papers receiving 456 citations
Peers
Comparison fields: 5 of 76
- Biomaterials 147
- Microbiology 66
- Immunology 156
- Pharmaceutical Science 29
- Biotechnology 27
Countries citing papers authored by Junqiang Ding
This map shows the geographic impact of Junqiang Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junqiang Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junqiang Ding more than expected).
Fields of papers citing papers by Junqiang Ding
This network shows the impact of papers produced by Junqiang Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junqiang Ding. The network helps show where Junqiang Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Junqiang Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 105 | |
| 2 | 2022 | 64 | |
| 3 | 2021 | 51 | |
| 4 | 2019 | 39 | |
| 5 | 2019 | 33 | |
| 6 | 2021 | 24 | |
| 7 | 2018 | 22 | |
| 8 | 2018 | 20 | |
| 9 | 2021 | 20 | |
| 10 | 2022 | 16 | |
| 11 | 2018 | 15 | |
| 12 | 2022 | 11 | |
| 13 | 2024 | 9 | |
| 14 | 2019 | 9 | |
| 15 | 2022 | 9 | |
| 16 | 2020 | 7 | |
| 17 | 2024 | 2 | |
| 18 | 2024 | 1 |
About Junqiang Ding
Junqiang Ding is a scholar working on Immunology, Molecular Biology, Biomaterials, Biomedical Engineering and Oncology, having authored 18 papers that have together received 457 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (6 papers), Nanoparticle-Based Drug Delivery (6 papers), Immunotherapy and Immune Responses (5 papers), Immune cells in cancer (5 papers), Virus-based gene therapy research (4 papers), Cancer Research and Treatments (3 papers), CAR-T cell therapy research (3 papers) and Phagocytosis and Immune Regulation (2 papers). The work is most often cited by research in Biomaterials (147 citations), Microbiology (66 citations), Immunology (156 citations), Pharmaceutical Science (29 citations) and Biotechnology (27 citations). Junqiang Ding has collaborated with scholars based in China and South Korea. Frequent co-authors include Yanzhi Song, Xinrong Liu, Xihui Gao, Yihui Deng, Xiaoxiao Liu, Wuyuan Lu, Chongbing Liao, Mingqi Liu, Yawei Hu and Yuqing Su. Their work appears in journals such as Molecular Pharmaceutics, International Journal of Pharmaceutics, Acta Pharmaceutica Sinica B, ACS Biomaterials Science & Engineering and Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.